FULC Valuation

Fulcrum Therapeutics Inc

Add to Watchlist

Advanced Chart

7.810

-0.01(-0.128%)1D

Overview
Forecast
Valuation
Earnings

FULC Relative Valuation

FULC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FULC is overvalued; if below, it's undervalued.

Historical Valuation

Fulcrum Therapeutics Inc (FULC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.82. The fair price of Fulcrum Therapeutics Inc (FULC) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：7.79

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.87

P/B

Median3y

1.46

Median5y

2.14

1.99

FCF Yield

Median3y

-20.80

Median5y

-19.17

Competitors Valuation Multiple

The average P/S ratio for FULC's competitors is 2.42, providing a benchmark for relative valuation. Fulcrum Therapeutics Inc Corp (FULC) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

FULC.O

Fulcrum Therapeutics Inc

Loss

Average P/S: 2.42

422.12M